BlackRock’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,832,755
| Closed | -$50.2M | – | 5688 |
|
|
2025
Q4 | $50.2M | Buy |
3,832,755
+344,553
| +10% | +$4.12M | ﹤0.01% | 2516 |
|
|
2025
Q3 | $25.4M | Sell |
3,488,202
-210,554
| -6% | -$1.42M | ﹤0.01% | 2937 |
|
|
2025
Q2 | $19.8M | Sell |
3,698,756
-129,714
| -3% | -$629K | ﹤0.01% | 3026 |
|
|
2025
Q1 | $20.4M | Sell |
3,828,470
-68,395
| -2% | -$478K | ﹤0.01% | 2926 |
|
|
2024
Q4 | $34.8M | Buy |
3,896,865
+397,387
| +11% | +$4.22M | ﹤0.01% | 2688 |
|
|
2024
Q3 | $38.5M | Sell |
3,499,478
-18,102
| -0.5% | -$201K | ﹤0.01% | 2641 |
|
|
2024
Q2 | $32M | Sell |
3,517,580
-67,913
| -2% | -$663K | ﹤0.01% | 2704 |
|
|
2024
Q1 | $50.5M | Buy |
3,585,493
+1,400,935
| +64% | +$17.4M | ﹤0.01% | 2435 |
|
|
2023
Q4 | $16.8M | Buy |
2,184,558
+495,722
| +29% | +$2.74M | ﹤0.01% | 3108 |
|
|
2023
Q3 | $12.6M | Buy |
1,688,836
+36,326
| +2% | +$310K | ﹤0.01% | 3192 |
|
|
2023
Q2 | $13.8M | Buy |
1,652,510
+1,364,141
| +473% | +$15.7M | ﹤0.01% | 3259 |
|
|
2023
Q1 | $3.84M | Buy |
288,369
+196,770
| +215% | +$2.66M | ﹤0.01% | 3750 |
|
|
2022
Q4 | $1.36M | Buy |
91,599
+13,274
| +17% | +$137K | ﹤0.01% | 4299 |
|
|
2022
Q3 | $708K | Buy |
78,325
+16,868
| +27% | +$113K | ﹤0.01% | 4613 |
|
|
2022
Q2 | $185K | Buy |
61,457
+11,071
| +22% | +$49.6K | ﹤0.01% | 5055 |
|
|
2022
Q1 | $338K | Sell |
50,386
-2,687
| -5% | -$16K | ﹤0.01% | 4979 |
|
|
2021
Q4 | $287K | Buy |
53,073
+11,957
| +29% | +$78.6K | ﹤0.01% | 5019 |
|
|
2021
Q3 | $363K | Buy |
41,116
+1,780
| +5% | +$17.1K | ﹤0.01% | 4843 |
|
|
2021
Q2 | $497K | Sell |
39,336
-163,827
| -81% | -$2.13M | ﹤0.01% | 4699 |
|
|
2021
Q1 | $3.52M | Buy |
203,163
+8,699
| +4% | +$157K | ﹤0.01% | 4089 |
|
|
2020
Q4 | $2.5M | Buy |
194,464
+8,569
| +5% | +$153K | ﹤0.01% | 3970 |
|
|
2020
Q3 | $6.9M | Buy |
185,895
+1,209
| +0.7% | +$47.9K | ﹤0.01% | 3429 |
|
|
2020
Q2 | $7.13M | Buy |
184,686
+145,147
| +367% | +$5.17M | ﹤0.01% | 3376 |
|
|
2020
Q1 | $985K | Buy |
39,539
+2,232
| +6% | +$69.2K | ﹤0.01% | 3875 |
|
|
2019
Q4 | $1.32M | Buy |
37,307
+9,009
| +32% | +$284K | ﹤0.01% | 3915 |
|
|
2019
Q3 | $917K | Sell |
28,298
-482
| -2% | -$19.1K | ﹤0.01% | 4011 |
|
|
2019
Q2 | $1.39M | Buy |
28,780
+18,744
| +187% | +$850K | ﹤0.01% | 3902 |
|
|
2019
Q1 | $476K | Buy |
+10,036
| New | +$340K | ﹤0.01% | 4107 |
|
|
2018
Q4 | – | Sell |
-2,838
| Closed | -$136K | – | 4950 |
|
|
2018
Q3 | $136K | Buy |
2,838
+1,656
| +140% | +$74.4K | ﹤0.01% | 4400 |
|
|
2018
Q2 | $68K | Buy |
1,182
+602
| +104% | +$55.5K | ﹤0.01% | 4520 |
|
|
2018
Q1 | $63K | Sell |
580
-11
| -2% | -$1.1K | ﹤0.01% | 4411 |
|
|
2017
Q4 | $53K | Buy |
591
+25
| +4% | +$2.94K | ﹤0.01% | 4425 |
|
|
2017
Q3 | $72K | Sell |
566
-22
| -4% | -$1.83K | ﹤0.01% | 4417 |
|
|
2017
Q2 | $50K | Buy |
588
+260
| +79% | +$21.6K | ﹤0.01% | 4525 |
|
|
2017
Q1 | $32K | Buy |
+328
| New | +$45.2K | ﹤0.01% | 4533 |
|
BlackRock's ATXS Position: Q1 2026 in Review
BlackRock sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 3,832,755 shares — an estimated $50.2M sold.
BlackRock first reported a position in ATXS in Q1 2017 and held it in 35 quarters. The position peaked at $50.5M in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- BlackRock reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- BlackRock sold 3,832,755 Astria Therapeutics shares in Q1 2026, an estimated $50.2M.
- BlackRock first reported a position in Astria Therapeutics in Q1 2017 and held it in 35 quarters.
- BlackRock's Astria Therapeutics position peaked at $50.5M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.